{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:16:47Z","timestamp":1791685007280,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40265-018-1010-7","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T03:49:18Z","timestamp":1542685758000},"page":"1817-1828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection"],"prefix":"10.1007","volume":"78","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"1010_CR1","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. https:\/\/aidsinfo.nih.gov\/guidelines . Accessed 30 Oct 2018."},{"key":"1010_CR2","doi-asserted-by":"crossref","unstructured":"British HIV Association. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. 2015 (2016 interim update). http:\/\/www.bhiva.org . Accessed 30 Oct 2018.","DOI":"10.21864\/jbgtha.2016.13"},{"key":"1010_CR3","unstructured":"European AIDS Clinical Society. Guidelines Version 9.1. 2018. http:\/\/eacsociety.org . Accessed 30 Oct 2018."},{"issue":"4","key":"1010_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379\u201396.","journal-title":"JAMA"},{"issue":"36","key":"1010_CR5","first-page":"1","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, et al. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14(36):1\u201316.","journal-title":"Retrovirology"},{"issue":"4","key":"1010_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5582\/bst.2017.01194","volume":"11","author":"Q Tang","year":"2017","unstructured":"Tang Q, Lu H. Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors. Biosci Trends. 2017;11(4):490\u20135.","journal-title":"Biosci Trends"},{"issue":"4","key":"1010_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1060028016682531","volume":"51","author":"JC Sebaaly","year":"2017","unstructured":"Sebaaly JC, Kelley D. Single-tablet regimens for the treatment of HIV-1 infection. Ann Pharmacother. 2017;51(4):332\u201344.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1010_CR8","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086\u201397.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1010_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01695-17","volume":"61","author":"SA Hassounah","year":"2017","unstructured":"Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61(12):1\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1010_CR10","unstructured":"Gilead Sciences. Biktarvy 50\u00a0mg\/200\u00a0mg\/25\u00a0mg film-coated tablets: EU summary of product characteristics. 2018. http:\/\/www.ema.europa.eu\/ . Accessed 30 Oct 2018."},{"key":"1010_CR11","unstructured":"Gilead Sciences. Biktarvy\u00ae (bictegravir, emtricitabine, and tenofovir alafenamide): US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/ . Accessed 30 Oct 2018."},{"issue":"4","key":"1010_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001726","volume":"32","author":"U Neogi","year":"2018","unstructured":"Neogi U, Singh K, Aralaguppe SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018;32(4):469\u201376.","journal-title":"AIDS"},{"issue":"37","key":"1010_CR13","first-page":"1","volume":"15","author":"SJ Smith","year":"2018","unstructured":"Smith SJ, Zhao XZ, Burke TR Jr, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(37):1\u201318.","journal-title":"Retrovirology"},{"issue":"Suppl. 1","key":"1010_CR14","first-page":"204s","volume":"25","author":"KL White","year":"2017","unstructured":"White KL, Niedziela-Majka A, Novikov N, et al. Bictegravir dissociation half-life from HIV-1 G140s\u2009+\u2009Q148H integrase\/DNA complexes [abstract no. 497]. Top Antivir Med. 2017;25(Suppl. 1):204s\u20135s.","journal-title":"Top Antivir Med"},{"issue":"Suppl. 1","key":"1010_CR15","first-page":"233s","volume":"26","author":"BG Brenner","year":"2018","unstructured":"Brenner BG, Oliveira M, Ibanescu RI, et al. In vitro selected resistance to new integrase inhibitors by B & non-B subtype viruses [abstract no. 549]. Top Antivir Med. 2018;26(Suppl. 1):233s.","journal-title":"Top Antivir Med"},{"key":"1010_CR16","unstructured":"US FDA. Application number: 210251Orig1s000 multi-discipline review. 2017. https:\/\/www.accessdata.fda.gov\/ . Accessed 30 Oct 2018."},{"issue":"1","key":"1010_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","volume":"15","author":"M Oliveira","year":"2018","unstructured":"Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56.","journal-title":"Retrovirology"},{"issue":"10107","key":"1010_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382.","journal-title":"Lancet"},{"issue":"10107","key":"1010_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372.","journal-title":"Lancet"},{"issue":"7","key":"1010_CR20","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, De Jesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48\u00a0week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347\u201356.","journal-title":"Lancet HIV"},{"issue":"7","key":"1010_CR21","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"J-M Molina","year":"2018","unstructured":"Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48\u00a0week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357\u201365.","journal-title":"Lancet HIV"},{"key":"1010_CR22","unstructured":"Kityo C, Hagins D, Koenig E, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in women [poster no. 500]. In: Conference on Retroviruses and Opportunistic Infections. 2018."},{"key":"1010_CR23","unstructured":"Acosta R, White K, Garner W, et al. HIV-1 subtype (B or non-B) had no impact on the efficacy of B\/F\/TAF or resistance development in five phase 3 treatment-naive or switch studies [abstract no. THPEB077]. In: 22nd International AIDS Conference. 2018."},{"issue":"11","key":"1010_CR24","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/infdis\/jiy428","volume":"218","author":"WW Zhang","year":"2018","unstructured":"Zhang WW, Cheung PK, Oliviera N, et al. Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis. 2018;218(11):1773\u20136.","journal-title":"J Infect Dis."},{"issue":"3","key":"1010_CR25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ndt\/gfw064","volume":"32","author":"J Milburn","year":"2017","unstructured":"Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1010_CR26","unstructured":"Zhang H, West S, Vu A, et al. A study evaluating the pharmacokinetics, safety, and tolerability of the bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) single tablet regimen (STR) in Japanese subjects [abstract no. MOPEB0332]. In: 9th International AIDS Society Conference on HIV Science. 2017."},{"key":"1010_CR27","doi-asserted-by":"crossref","unstructured":"Wohl DA, Yazdanpanah Y, Baumgarten A, et al. A phase 3, randomized, controlled clinical trial of bictegravir in a fixed-dose combination, B\/F\/TAF, vs ABC\/DTG\/3TC in treatment-na\u00efve adults at week 96 [abstract no. LB4]. In: IDWeek. 2018.","DOI":"10.1093\/ofid\/ofy229.2178"},{"key":"1010_CR28","unstructured":"Stellbrink HJ, Arribas J, Stephens JL, et al. Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC\/TAF in a fixed-dose combination (B\/F\/TAF) versus dolutegravir (DTG)\u2009+\u2009F\/TAF in treatment-na\u00efve HIV-1 positive adults: week 96 [abstract plus presentation]. In: HIV Drug Therapy Conference. 2018."},{"issue":"5","key":"1010_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"D Wohl","year":"2018","unstructured":"Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11(5):561\u201373.","journal-title":"Patient."},{"key":"1010_CR30","unstructured":"Chuck S. Renal data at 96\u00a0weeks for study 1490. California: Gilead Sciences. 2018. (Data on file)."},{"issue":"2","key":"1010_CR31","first-page":"89","volume":"18","author":"JC Yombi","year":"2016","unstructured":"Yombi JC, Pozniak AL. Is it time for integrase inhibitors to be the preferred regimen for the first-line treatment of HIV-1-infected naive patients? AIDS Rev. 2016;18(2):89\u2013100.","journal-title":"AIDS Rev"},{"issue":"10123","key":"1010_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","volume":"391","author":"JM Llibre","year":"2018","unstructured":"Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839\u201349.","journal-title":"Lancet"},{"issue":"5","key":"1010_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","volume":"76","author":"J Norwood","year":"2017","unstructured":"Norwood J, Turner M, Bofill C, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"1010_CR34","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/jac\/dky145","volume":"73","author":"DR Bakal","year":"2018","unstructured":"Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177\u201385.","journal-title":"J Antimicrob Chemother"},{"key":"1010_CR35","unstructured":"European Medicines Agency. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir [media release]. http:\/\/www.ema.europa.eu . Accessed 18 May 2018."},{"key":"1010_CR36","unstructured":"ViiV Healthcare UK Ltd. Triumeq 50\u00a0mg\/600\u00a0mg\/300\u00a0mg film-coated tablets: EU summary of product characteristics. 2018. http:\/\/www.ema.europa.eu\/ . Accessed 30 Oct 2018."},{"key":"1010_CR37","unstructured":"ViiV Healthcare UK Ltd. Juluca 50\u00a0mg\/25\u00a0mg film-coated tablets: EU summary of product characteristics. 2018. http:\/\/www.ema.europa.eu\/ema\/ . Accessed 30 Oct 2018."},{"key":"1010_CR38","doi-asserted-by":"crossref","unstructured":"ViiV Healthcare. Juluca (dolutegravir and rilpivirine) tablets, for oral use: US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/ . Accessed 30 Oct 2018.","DOI":"10.26226\/morressier.5b1e3f843b8238060ea91292"}],"updated-by":[{"DOI":"10.1007\/s40265-019-01101-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1010-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1010-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1010-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:57:26Z","timestamp":1775275046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1010-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":38,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1010-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"20 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817\ufffd\ufffd\ufffd1828 Gilead Sciences requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Gilead Sciences. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (\n                      \n                      ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817\ufffd\ufffd\ufffd1828 Gilead Sciences requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Gilead Sciences. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (\n                      \n                      ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817\ufffd\ufffd\ufffd1828 Gilead Sciences requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Gilead Sciences. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (\n                      \n                      ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emma Deeks is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}